Preclinical Trial-on-Chip Combination Therapy Screening Service

Online Inquiry

Background Service What We Can Offer Workflow HighlightsFAQs Contact

Current challenges in immuno-oncology include high clinical attrition rates and the inability of traditional animal models to reliably predict human tumor-immune-microenvironment (TIME) interactions. Creative Biolabs' Preclinical Trial-on-Chip Combination Therapy Screening Service directly addresses this translational gap. This service leverages advanced microfluidic "Trial-on-Chip" technology to co-culture patient-derived organoids with autologous immune components under physiological flow conditions. By delivering dynamic, high-content data on immune cell infiltration, tumor killing, and combination synergy, we enable data-driven optimization of therapeutic candidates, de-risking your pipeline and accelerating the path to clinical success.

Introduction

The translational progress of cancer immunotherapy is hindered by conventional preclinical models that fail to replicate the dynamic interplay within the human tumor-immune microenvironment. Consequently, the field is advancing toward more physiologically relevant systems, including patient-derived organoids (PDOs), microfluidic organ-on-a-chip platforms, and humanized patient-derived xenografts (PDXs). These models retain critical pathophysiological attributes such as perfusable vasculature and patient-matched immune populations. An integrated translational strategy now merges these platforms with functional genomic screening, multi‑omics analysis, and systematic in vivo validation. This unified approach enhances the predictive fidelity of preclinical data, effectively narrowing the divide between experimental findings and clinical application in precision immuno‑oncology.

Fig.1 Unified platform for contemporary preclinical screening. (OA Literature) Fig.1 Streamlined pipeline for advanced preclinical drug testing.¹

Preclinical Trial-on-Chip Combination Therapy Screening Service at Creative Biolabs

Creative Biolabs' Preclinical Trial-on-Chip Combination Therapy Screening Service leverages vascularized microphysiological systems to deliver human-relevant immunotherapy insights. It enables high-throughput screening of drug combinations within a dynamic tumor-immune microenvironment, providing multi-parametric data on efficacy and mechanism. This platform accelerates lead optimization and de-risks clinical translation by bridging the gap between conventional assays and costly in vivo studies.

What We Can Offer

Our Preclinical Trial-on-Chip Combination Therapy Screening Service integrates advanced technologies into a streamlined, physiologically relevant platform designed to de-risk your immuno-oncology pipeline. Below is a detailed breakdown of our core offerings.

Featured services of preclinical trial-on-chip combination therapy screening service at Creative Biolabs. (Creative Biolabs Original)

Our Service Process

Required Starting Materials:

Candidate drug libraries or lead compound structures.
Specific tumor cell lines or cryopreserved patient-derived primary cells.
Target profiles.

Key Steps:

Workflow of preclinical trial-on-chip combination therapy screening service at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables: Upon completion of the screening study, you will be provided with a detailed Synergy Analysis Report, high-definition visualizations of immune-oncology interactions, and a complete, exportable dataset containing dose-response metrics.

Key Advantages

Tailored Microfluidic Design: Our platform offers comprehensive customization of chip geometry and microstructure to precisely replicate the unique cellular composition and pathophysiology of your target tissue or disease model.
Scalable High-Throughput Operation: The integrated system supports parallel screening of over 100,000 unique pharmacodynamic data points, enabling simultaneous analysis of multi‑compound dose‑response matrices within a single workflow.
Sustained Specimen Integrity: We ensure continuous viability and functional consistency of patient-derived samples, including primary cells, patient-derived organoids, and immune components, throughout extended dynamic perfusion studies, validated by rigorous quality controls.

FAQs

Q1: Is simultaneous testing of multiple combination therapies supported?

A1: Absolutely. Our high-throughput platform enables fully automated, multi-dimensional screening of drug-drug interactions, generating thousands of pharmacodynamic data points within a single integrated study.

Q2: How does this approach surpass conventional 3D organoid models in static plates?

A2: Unlike static organoids, our functional microphysiological system recapitulates dynamic human tissue microenvironments through integrated perfusable vasculature, physiological shear stress, and spatially regulated oxygen gradients, critical factors for accurate prediction of pharmacokinetics and therapeutic efficacy in vivo.

Why Choose Us?

We integrate advanced microfluidic engineering with deep immunology expertise. Our platform overcomes traditional limitations by combining vascularized tissue models, patient-derived immune cells, and automated high-content analysis. This provides clinically predictive human-relevant data, de-risking your combination immunotherapy development and accelerating the path to IND submission.

Customer Reviews

"Integrating the Trial-on-Chip platform markedly advanced our ability to identify treatment‑resistant colorectal cancer subgroups. The strong clinical concordance provided critical validation that supported our clinical development decision."

— Dr. A***n H.

"We successfully migrated our patient‑derived organoid biobank onto the microphysiological system with minimal disruption. The real‑time visualization of immune cell transmigration offered unprecedented insight into stromal‑immune dynamics in solid tumors."

— Prof. M***s L.

"The analytically rigorous synergy mapping was instrumental during candidate prioritization. This approach revealed cooperative drug interactions that conventional monolayer screens consistently failed to detect."

— Dr. S***a K.

How to Contact Us?

Unlock high-fidelity clinical foresight with our Trial-on-Chip platform, integrating vascularized microfluidics, patient-derived biology, and synergy modeling. Ready to de-risk and accelerate your combination therapy pipeline? Contact our experts today for a tailored consultation and quotation.

Reference

Motohashi, Shohei et al. "Advances and Challenges in Drug Screening for Cancer Therapy: A Comprehensive Review." Bioengineering (Basel, Switzerland) vol. 12,12 1315. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3390/bioengineering12121315.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.